Fresenius Medical Care (NYSE:FMS) Earns Strong-Buy Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Friday. The firm set a “strong-buy” rating on the stock.

Separately, Morgan Stanley lowered shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $32.25.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $20.23 on Friday. The stock has a market capitalization of $11.87 billion, a P/E ratio of 21.98, a P/E/G ratio of 1.18 and a beta of 1.00. Fresenius Medical Care has a 12-month low of $16.37 and a 12-month high of $27.72. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.42 and a quick ratio of 1.07. The firm’s 50-day moving average is $19.53 and its two-hundred day moving average is $19.47.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.11. The business had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. Equities analysts predict that Fresenius Medical Care will post 1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Veracity Capital LLC raised its holdings in Fresenius Medical Care by 172.2% in the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock valued at $1,022,000 after buying an additional 33,543 shares during the period. Legacy Wealth Asset Management LLC purchased a new position in Fresenius Medical Care in the first quarter valued at approximately $584,000. Uncommon Cents Investing LLC raised its holdings in Fresenius Medical Care by 8.0% in the first quarter. Uncommon Cents Investing LLC now owns 38,810 shares of the company’s stock valued at $748,000 after buying an additional 2,890 shares during the period. GAMMA Investing LLC raised its holdings in Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after buying an additional 758 shares during the period. Finally, Morningstar Investment Services LLC raised its holdings in Fresenius Medical Care by 104.3% in the fourth quarter. Morningstar Investment Services LLC now owns 20,729 shares of the company’s stock valued at $434,000 after buying an additional 10,584 shares during the period. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.